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ling. METHODS: A cross-sectional study design using convenience sampling tech-
nique was used in this study. A validated self-administered questionnaire using 5 point 
Likert scale was distributed to 440 respondents in the State of Penang, Malaysia. The 
Statistical Package of Social Science (SPSS Inc., Chicago, IL) for Windows version 12.0 
was used for all the statistical tests and a p-value of <0.05 was considered statistically 
signiﬁ cant. RESULTS: The result revealed that majority of the respondents (69.3%), 
understand the roles of community pharmacists in patients’ education and counselling. 
More than half of them (66.3%) are aware of the availability of medical counselling 
provided by community pharmacists. Majority of the respondents (66.8%), are aware 
that community pharmacists are well-trained to provide medical education and counsel-
ling. On the other hand, less than half of the respondents (46.6%) perceive that phar-
macists are the best people to provide medical education and counselling to the public. 
About 70% of the respondents had mentioned that the pharmacist will ask them about 
their medical conditions and allergies before recommending any medications. Respon-
dents also found that: pharmacists are very approachable for giving medical education 
and counselling (56.4%); community pharmacists help them to explain the misconcep-
tions that they had in health care (59.0%); they have changed for healthier lifestyles 
after being exposed to medical education and counselling by community pharmacists 
(58.2%). CONCLUSIONS: The present study also found that the respondents are 
generally well aware and satisﬁ ed toward the medical education and counselling 
provided by community pharmacists in the state of Penang, Malaysia. 
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OBJECTIVES: To determine the effect of including the costs and risks of medical 
negligence claims on the results of a cost-utility model of diagnostic strategies for 
patients with chest pain presenting at the Emergency Room. Coronary computed 
tomography (CT) has been proposed as an initial screening technique for patients at 
low risk of coronary artery disease, because it may allow earlier discharge and cost 
savings compared with stress-based tests such as exercise single-photon emitting 
computed tomography (SPECT) or exercise echocardiography (E x E). METHODS: 
A decision-analytic model was designed to calculate the expected costs and health 
outcomes at 12 months for patients at low risk of coronary artery disease presenting 
at the Emergency Room with chest pain. Published data was used to predict the 
accuracies of the diagnostic tests. Costs were calculated from the perspective of the 
Australian health system, and a rate (30%) and cost of litigation ($160,000) was 
included for false negative diagnoses that incurred an event within the time frame. 
RESULTS: ExE was the least costly strategy in the base case analysis. The results are 
sensitive to changes in the cost and likelihood of litigation, because these costs are 
high relative to the other costs in the model. At a 30% claim rate, if the expected 
payout for litigation is <$150,000, CT is the most cost-effective option, with lower 
costs and higher QALYs. The ICERs are high because the differences in QALYs are 
small. In contrast, at the expected cost of litigation in the United States ($1,000,000), 
the strategy with lowest event rate (SPECT) is the least costly strategy. CONCLU-
SIONS: Litigation costs for medical negligence can change the outcomes of cost-utility 
analyses. We consider that these should be assessed and included when an analysis is 
undertaken from the societal perspective. 
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OBJECTIVES: To evaluate knowledge and perceptions of Malaysian general medical 
practitioners (GPs) on issues surrounding the safety, efﬁ cacy, and quality of generic 
medicines. METHODS: A postal cross-sectional survey involving registered GPs (n = 
325) in Penang, Malaysia was undertaken. The questionnaire consisted 23-item and 
validated accordingly before it been sent to the GPs. At the end of the survey period, 
a total of 87 GPs responded to the survey (Response rate of 26.8%). RESULTS: The 
majority of the respondents (85.1%) claimed that they actively prescribed generic 
medicines in their practice. On the other hand, only 4.6% of the respondents correctly 
identiﬁ ed the Malaysia’s National Pharmaceutical Control Bureau’s bioequivalence 
standard for generic products. There were misconceptions among the respondents 
about the concepts of “bioequivalence,” “efﬁ cacy,” “safety,” and “manufacturing 
standards” of generic medicines. GPs in this survey believed that a standard guideline 
on brand substitution process, collaboration with pharmacists, patient education and 
information on safety and efﬁ cacy of generic medicines were necessary to ensure 
quality use of generics. Furthermore, advertisements and product bonuses offered by 
pharmaceutical companies, patient’s socio-economic factors as well as credibility of 
manufacturers were factors reported to inﬂ uence their choice of medicine. CONCLU-
SIONS: As a conclusion, although it appeared that GPs have largely accepted the use 
of generic medicines, they still have concerns regarding the reliability and quality of 
such products. GPs need to be educated and reassured about generic products approval 
system in Malaysia concerning bioequivalence, quality, and safety. 
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OBJECTIVES: Much literature has proved that process of care in acute myocardial 
infarction (AMI) patients has signiﬁ cant effect on mortality and prognosis. However, 
little study has discussed about the association between hospital process performance 
and patients’ outcome. The objective of this study was to investigate the association 
between hospitals care process and patients’ outcome while controlling for potential 
confounders, including coexisting conditions, severity of illness and process perfor-
mance of hospitals in Taiwan. METHODS: The claimed data came from the National 
Health Insurance Research Database for inpatient treatment for AMI in 2007 to 2008. 
Totally 109 hospitals and 899 patients were enrolled in this study. Main outcome 
measures were 6 ACC/AHA class I guideline-recommended treatments and the correla-
tion between hospitals’ individual care processes performance and 30-day mortality 
rate of patients. We tested the association between the process and outcome for each 
hospital by using a hierarchical linear model (HLM) for each process measure. 
RESULTS: Over all, the average eligible rate among six ACC/AHA guideline-recom-
mended treatments was 42.38%. The eligible rate of reperfusion was signiﬁ cantly 
different between public, nonproﬁ t and private hospitals (P = 0.0004). Factors highly 
correlated with 30-day mortality rate of patients included using aspirin (OR = 0.97, 
P < 0.0001), using lipid-lowering agents (OR = 0.99, P = 0.005) and having reperfu-
sion (OR = 0.99, P = 0.05) at admission. CONCLUSIONS: Signiﬁ cant associations 
between hospital care process and patients’ outcomes were found. The results sup-
ported the use of guideline-based performance measures which can help improving 
hospital quality. 
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OBJECTIVES: Prophylaxis with a low molecular weight heparin (LMWH) such as 
enoxaparin or a low-dose unfractionated heparin (LDUH) in high risk medical and 
surgical patients is consistent with the recommendations made by the American 
College of Chest Physicians Eighth Conference on Antithrombotic and Thrombolytic 
Therapy. While these guidelines present strong evidence to support the use of prophy-
laxis to prevent venous thromboembolism (VTE), they are not always adhered to in 
clinical practice. The St. Vincent’s Private Hospital VTE Prevention Project aimed to 
improve compliance with best practice prophylaxis in hospitalized patients. An audit 
of the rates of prophylaxis was conducted over a 12-month period as part of this 
project. The aim of this analysis was to determine whether the measures implemented 
as a result of the St. Vincent’s project translated into cost savings and improved clinical 
outcomes. METHODS: A decision-analytic model was constructed using audit data 
from 21,942 medical and surgical patients admitted to St. Vincent’s who received 
either enoxaparin 40 mg daily, unfractionated heparin (UFH) three times daily (TID) 
or no prophylaxis. The rate of prophylaxis at baseline was compared with that at the 
end of the audit for each prophylaxis regimen. Clinical trial data was used to estimate 
the incidence of VTE (deﬁ ned as deep vein thrombosis [DVT] and pulmonary embo-
lism [PE]), and major bleeding. RESULTS: As a result of the measures introduced to 
improve adherence to best practice, we estimated 13 fewer deaths, 84 fewer symp-
tomatic DVTs, 19 fewer symptomatic PEs and 512 fewer hospital bed days over 
baseline, across all medical and surgical patients. We also estimated that overall costs 
were reduced by $245,439 over 12 months. CONCLUSIONS: Improved adherence 
to best practice in VTE prophylaxis in the Australian clinical setting is likely to result 
in fewer deaths, VTE events and signiﬁ cant overall cost savings. 
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INTERVENTION: APPLICATION OF A METHODOLOGICAL 
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OBJECTIVES: To assess the extent to which the development steps of the evaluation 
of care pathways (CP) can be represented in the framework for the design and evalu-
ation of complex interventions. METHODS: The framework is composed by ﬁ ve 
phases: theoretical (pre-clinical), identiﬁ cation of components of the intervention 
(phase I), deﬁ nition of trial and intervention design (phase II), main trial execution 
(phase III), promoting effective implementation (phase IV). RESULTS: The framework 
was applied to the evaluation of CP for strokes. Pre-clinical phase was aimed in 
synthesizing the evidences: three reviews were selected and showed that CP are theo-
retically applicable in stroke care and that mortality should be the main outcome to 
be analyzed. Phase I was done through a descriptive pilot. A total of 253 consecutive 
patients admitted for strokes in 29 hospitals were analyzed. Overall in-hospital stroke 
mortality was 19.76%. Stroke teams (OR = 0.25; P = 0.025), antithrombotic therapy 
(OR = 0.26; P = 0.009) and complications (OR = 6.40; P < 0.001) were independent 
predictors of in-hospital mortality. Therefore these variables were selected as 
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components of CP or treated as covariates. Because CP are active both on organiza-
tional (units) and individual (patients) level, a two-arm cluster Randomized Controlled 
Trial with hospitals and long-term rehabilitation facilities as randomization units was 
designed in phase II. Fourteen units were randomized either to arm 1 (CP) or to arm 
2 (usual care) including 238 patients per group. The primary outcome measure was 
mortality, the CP were also analyzed with key quality indicators. The trial has been 
successfully performed (phase III) and in-hospital mortality has been reduced (OR = 
0.10; P = 0.04). Because the adjusted results are not available yet, it was not possible 
to identify the active components of the CP and therefore phase IV has not been 
performed. CONCLUSIONS: Even if the results are still partial, it seems possible to 
apply this framework to the study of CP. 
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: 1) Compare efﬁ cacy and safety of sitagliptin and vildagliptin in type 
2 diabetes; and 2) Examine prescription of concomitant oral hypoglycemic agents 
(OHAs) and insulin. METHODS: We conducted a retrospective database study, 
drawing information from all patients treated at Singapore Health Services cluster 
institutions over 1.5-year study period. Inclusion criteria: HbA1C >7%, naive to 
gliptins, and remained on gliptin for at least 90 days (from pharmacy records). Exclu-
sion criteria: patients who switched gliptins, and HbA1c not tested within 10 days of 
exit timepoint. IRB approval was obtained. RESULTS: Sitagliptin (n = 340) and 
vildagliptin (n = 92) patients met inclusion and exclusion criteria. General demograph-
ics matched at baseline (all P > 0.05). Mean duration of gliptin treatment 242 days 
(sitagliptin) versus 220 days (vildagliptin) (P = 0.944). Mean baseline HbA1c matched 
at 8.95% (sitagliptin) versus 9.18% (vildagliptin) (P = 0.15). At exit, sitagliptin arm 
demonstrated absolute HbA1c reduction of −0.643% versus vildagliptin −0.728% (P 
= 0.61); percentage reduction in HbA1c was sitagliptin −6.55% versus vildagliptin 
−7.589% (p = 0.44). Subgroup analyses of a) patients with entry HbA1c >8%; b) 
stratiﬁ cation of outcome by dose of gliptin; and c) addition or discontinuation of OHA 
from baseline all did not demonstrate statistically signiﬁ cant difference. Majority of 
patients were not on maximal OHA doses at gliptin initiation, however total daily 
doses of OHAs was not signiﬁ cantly different at exit versus baseline for both arms. 
Almost 90% of patients in both groups received multiple OHAs for diabetes control. 
Change in creatinine clearance was comparable in both arms. Safety endpoints micro-
albuminuria/creatinine ratio, average % weight change and incidence of pancreatitis 
were not signiﬁ cantly different between both arms (all P > 0.05). Five sitagliptin 
patients required hospital admission for severe hypoglycemia vs 0 vildagliptin patients. 
CONCLUSIONS: We present our initial ﬁ ndings that vildagliptin is non-inferior to 
sitagliptin in HbA1c-lowering efﬁ cacy. Both products are well-tolerated without sig-
niﬁ cant differences in safety endpoints save severe hypoglycemia in sitagliptin arm. 
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OBJECTIVES: To evaluate the long-term health outcomes associated with Liraglutide 
1.2 and 1.8 mg versus Glimepiride 4 mg all combined with Metformin in Asian 
patients with type 2 diabetes (T2D). METHODS: A published and validated computer 
simulation model of diabetes (CORE Diabetes Model) was used to make the projection 
of long-term health outcomes (30 years). Simulated cohorts and treatment effects were 
derived from 928 T2D patients in the NCT00614120 trial held in China, South Korea 
and India. HbA1C was signiﬁ cantly reduced in Liraglutide 1.2 mg, Liraglutide 1.8 mg, 
and Glimepiride groups (−1.3%, −1.4%, and −1.3% respectively). Liraglutide treat-
ments led to greater reduction in Body Mass Index and systolic blood pressure versus 
Glimepride. No major hypoglycemia was reported in Liraglutide groups, while the 
rate of major hypoglycemia for Glimepride was 0.029 per patient-year. The rate of 
minor hypoglycemia was lower in Liraglutide groups than Glimepiride. An annual 
discounting rate of 3% was used for health and cost outcomes. One-way sensitivity 
analysis was performed. RESULTS: The treatments of Liraglutide compared with 
Glimepiride were projected to reduce the cumulative incidences of diabetes complica-
tions and improve long term health outcomes for patients with T2D. For Liraglutide 
1.2 mg, the cumulative incidences of background retinopathy, end stage renal disease, 
ulcer, and congestive heart failure event were reduced 0.20%, 0.086%, 0.020% and 
0.53% respectively, discounted life expectancy was increased 0.058 year and quality 
adjusted life-years (QALY) was increased 0.11 QALY. For Liraglutide 1.8mg, the 
incidences reduction were 0.61%, 0.12%, 0.34% and 0.63% respectively, discounted 
life expectancy was improved 0.051 year, and 0.107 QALY. CONCLUSIONS: Lira-
glutide 1.2 mg and 1.8 mg therapy could delay the onset of diabetes complications 
and reduced related cumulative incidences over patient lifetimes compared with 
Glimepiride. It improved the life expectancy and quality adjusted life expectancy in 
Asian patients with T2D. 
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OBJECTIVES: To address effects of extended-release versus immediate-release glipi-
zide on glucose control, insulin secretion, and compliance. METHODS: We included 
parallel randomized trials and cohort studies (only for compliance assessment) com-
paring extended-release versus immediate-release glipizide for type 2 diabetes. We 
searched Medline, EMBASE, the Cochrane Library, and Chinese Biomedical database, 
screened reference lists, and contacted pharmaceutical company. We pooled data using 
random-effect model and explored heterogeneity by pre-speciﬁ ed hypotheses. 
RESULTS: Sixteen trials involving 1062 patients and two retrospective cohort studies 
of 13,452 patients were included. Trials are of inadequate quality. No trials reported 
patient-important outcomes. The reduction of fasting plasma glucose from the baseline 
appeared larger in extended-release than immediate-release glipizide (mean difference 
−0.30 mmol/L, 95% CI −0.57 to −0.03). The reduction was not signiﬁ cant different 
between two drugs in HbA1c (−0.03%, −0.20% to 0.15%) and 2-hour postprandial 
plasma glucose (−0.28 mmol/L, −1.12 to 0.55). Extended-release glipizide appeared 
to reduce insulin secretion from the baseline, whereas immediate-release formulation 
increased the secretion (fasting insulin: −0.86 vs. 0.28 μIU/ml; 2-hour postprandial 
insulin: −2.94 vs. 0.24 μIU/ml). Patients administering extended-release glipizide had 
less hypoglycemia (Peto odds ratio 0.26, 95% CI 0.08 to 0.81) and lower missed 
dosing (Peto odds ratio 10.24, 95%CI 5.22 to 20.08). The cohort studies showed 
results in compliance consistent with trials. CONCLUSIONS: The two drugs may 
have comparable effects on glucose control. Extended-release glipizide might achieve 
glucose control with decreased insulin secretion, and fewer hypoglycemic episodes. 
The ﬁ ndings are inconclusive due to inadequate study quality, short follow-up, and 
unavailability of patient important outcomes. 
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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OBJECTIVES: To assess overall and diabetes-related medical service costs associated 
with pioglitazone (PIO) and sulfonylureas (SU) treatment among T2DM patients. 
METHODS: This is a retrospective cohort study based on electronic medical records 
(January 1, 2004–January 31, 2009) from the Geisinger Clinic in the Northeastern 
region of the United States. The date of the initial prescription for PIO or SU was 
denoted as the index date. Patients were required to be aged 18 years or older and 
prescribed an oral antidiabetic treatment in the 1 year prior to index. Patients with 
type 1 or gestational diabetes and prior insulin use were excluded, as were those who 
had prescriptions for the index drug in the 90 days prior. Propensity score 1:1 match-
ing and a second stage of generalized linear regression were employed to assess overall 
and diabetes-related medical service costs (pharmacy costs were not available in the 
database) in the 2 years following the index date, adjusting for patient demographics, 
baseline comorbidities, medication use, and health-care resource utilization. RESULTS: 
A total of 2758 patients, 1379 each in the PIO and SU cohorts, were analyzed. For 
both cohorts, mean age was 62 years, 46% were male, and 96% were Caucasian. The 
two cohorts were similar in terms of current smoking status and diabetes-related 
comorbidities. The unadjusted total and diabetes-related medical costs were $1258 
and $705 higher for SU versus PIO patients. After adjusting for covariates, the overall 
and diabetes-related medical service costs remained higher for patients receiving SU 
versus PIO ($8360 vs. $7400 for overall, and $5577 vs. $5238 for diabetes-related 
costs, P < 0.05 for both comparisons). CONCLUSIONS: Over a 2-year follow-up, 
patients with T2DM initiated on PIO therapy in an integrated system incurred lower 
overall and diabetes-related medical service costs than patients initiated on SU. Further 
studies describing clinical and humanistic aspects of PIO versus SU are warranted. 
PDB5
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OBJECTIVES: To estimate annual health-care costs associated with hypoglycemia 
among T2DM patients initiated on oral antidiabetic drugs (OADs) in a large managed 
care cohort with managed care insurance beneﬁ ts. METHODS: T2DM patients initi-
ated on OADs were selected from the Ingenix Impact database (1999–2008). Patients 
aged 18 years or older with at least 1 year of continuous eligibility following the index 
date (the ﬁ rst OAD prescription ﬁ ll date) who were diagnosed with moderate to severe 
